To develop such an inhibitor, we first utilized in silico screening with a machine learning platform and identified SMC #13 as a potential inducer of WASp degradation, thereby blocking WASp-dependent cytoskeletal dynamics in hematological cancers. Here, WAS is linked to hematopoietic and lymphoid cell neoplasm.